S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
Log in
NASDAQ:MYGN

Myriad Genetics Stock Forecast, Price & News

$26.71
+0.91 (+3.53 %)
(As of 01/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$25.52
Now: $26.71
$27.00
50-Day Range
$17.54
MA: $19.93
$25.80
52-Week Range
$9.24
Now: $26.71
$30.13
Volume806,735 shs
Average Volume894,681 shs
Market Capitalization$2.01 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.71
Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with deleterious or suspected deleterious germline; GeneSight, a DNA genotyping test to aid psychotropic drug selection for depressed patients; and Vectra, a protein quantification test for assessing the disease activity of rheumatoid arthritis. In addition, the company offers Foresight, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; Prequel, a non-invasive prenatal screening test to screen for severe chromosomal disorders in a fetus; and Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer. Further, it provides EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice CDx, a companion diagnostic to measure three modes of homologous recombination deficiency comprising loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions in cancer cells. Additionally, the company offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.
Myriad Genetics logo

MarketRank

Overall MarketRank

1.15 out of 5 stars

Medical Sector

771st out of 1,558 stocks

Diagnostic Substances Industry

16th out of 28 stocks

Analyst Opinion: 0.7Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:MYGN
CUSIP62855J10
Phone801-584-3600
Employees2,700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$638.60 million
Cash Flow$0.66 per share
Book Value$12.32 per share

Profitability

Net Income$-199,500,000.00

Miscellaneous

Market Cap$2.01 billion
Next Earnings Date2/4/2021 (Estimated)
OptionableOptionable
$26.71
+0.91 (+3.53 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MYGN News and Ratings via Email

Sign-up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Myriad Genetics (NASDAQ:MYGN) Frequently Asked Questions

How has Myriad Genetics' stock been impacted by Coronavirus?

Myriad Genetics' stock was trading at $14.03 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MYGN shares have increased by 90.4% and is now trading at $26.71.
View which stocks have been most impacted by COVID-19
.

Is Myriad Genetics a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last twelve months. There are currently 3 sell ratings and 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "sell" Myriad Genetics stock.
View analyst ratings for Myriad Genetics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Myriad Genetics?

Wall Street analysts have given Myriad Genetics a "Sell" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Myriad Genetics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Myriad Genetics' next earnings date?

Myriad Genetics is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for Myriad Genetics
.

How were Myriad Genetics' earnings last quarter?

Myriad Genetics, Inc. (NASDAQ:MYGN) announced its earnings results on Monday, November, 9th. The company reported ($0.15) EPS for the quarter, beating the Zacks' consensus estimate of ($0.30) by $0.15. The business had revenue of $145.20 million for the quarter, compared to analyst estimates of $134.59 million. Myriad Genetics had a negative return on equity of 4.07% and a negative net margin of 32.49%. Myriad Genetics's quarterly revenue was down 22.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.08 EPS.
View Myriad Genetics' earnings history
.

What price target have analysts set for MYGN?

5 brokers have issued twelve-month target prices for Myriad Genetics' shares. Their forecasts range from $10.00 to $18.00. On average, they anticipate Myriad Genetics' share price to reach $13.25 in the next twelve months. This suggests that the stock has a possible downside of 50.4%.
View analysts' price targets for Myriad Genetics
or view Wall Street analyst' top-rated stocks.

Who are some of Myriad Genetics' key competitors?

What other stocks do shareholders of Myriad Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Myriad Genetics investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Gilead Sciences (GILD), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), AT&T (T), Alibaba Group (BABA) and Kratos Defense & Security Solutions (KTOS).

Who are Myriad Genetics' key executives?

Myriad Genetics' management team includes the following people:
  • Mr. R. Bryan Riggsbee, Exec. VP, CFO & Treasurer (Age 49, Pay $741.84k)
  • Dr. Jerry S. Lanchbury, Chief Scientific Officer (Age 61, Pay $632.04k)
  • Ms. Nicole Lambert, Group Pres of Myriad Oncology, Myriad Women's Health & Myriad International (Age 45, Pay $507.51k)
  • Mr. Paul J. Diaz, CEO, Pres & Director (Age 58)
  • Mr. Scott Gleason, Sr. VP of Investor Relations
  • Mr. Benjamin Jackson, Exec. VP, Gen. Counsel & Sec. (Age 41)
  • Dr. Clivetty Martinez, Chief Compliance Officer
  • Ms. Jayne Baird Hart, Exec. VP of HR (Age 60)
  • Mr. Paul Chip Parkinson, Exec. VP of Reimbursement Strategy
  • Mr. Mark S. Verratti, Pres of Myriad Neuroscience & Myriad Autoimmune (Age 52)

What is Myriad Genetics' stock symbol?

Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."

Who are Myriad Genetics' major shareholders?

Myriad Genetics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include State of Alaska Department of Revenue (0.08%). Company insiders that own Myriad Genetics stock include Alexander Ford, Bernard Tobin, Gary A King, John T Henderson, Nicole Lambert, Paul Parkinson, Ralph L Mcdade, Richard Bryan Riggsbee, S Louise Phanstiel and Walter Phd Gilbert.
View institutional ownership trends for Myriad Genetics
.

Which major investors are selling Myriad Genetics stock?

MYGN stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have sold Myriad Genetics company stock in the last year include Alexander Ford, Nicole Lambert, and Paul Parkinson.
View insider buying and selling activity for Myriad Genetics
or view top insider-selling stocks.

How do I buy shares of Myriad Genetics?

Shares of MYGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Myriad Genetics' stock price today?

One share of MYGN stock can currently be purchased for approximately $26.71.

How big of a company is Myriad Genetics?

Myriad Genetics has a market capitalization of $2.01 billion and generates $638.60 million in revenue each year. The company earns $-199,500,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis. Myriad Genetics employs 2,700 workers across the globe.

What is Myriad Genetics' official website?

The official website for Myriad Genetics is www.myriad.com.

How can I contact Myriad Genetics?

Myriad Genetics' mailing address is 320 WAKARA WAY, SALT LAKE CITY UT, 84108. The company can be reached via phone at 801-584-3600 or via email at [email protected]

This page was last updated on 1/17/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.